Results 91 to 100 of about 27,792 (251)

How informative is a negative finding in a small pharmacogenetic study? [PDF]

open access: yes, 2011
Many pharmacogenetic studies fail to yield any statistically significant associations. Such negative findings may be due to the absence of, or inadequate statistical power to test for, an effect at the genetic variants tested.
Whittaker, JC   +5 more
core   +1 more source

Integrating Pharmacogenomic Testing Within the 4Ms Framework for Management of Behavioral Symptoms in Advanced Vascular Dementia: A Case Study

open access: yesJournal of the American Geriatrics Society, EarlyView.
Pharmacogenomic‐guided managment of behavioral symptoms within the 4Ms framework.
Gianna Franco   +3 more
wiley   +1 more source

Pharmacogenomics in Dentistry: From CYP‐Mediated Drug Response to Precision Prescribing in Oral Healthcare

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective This narrative review critically assesses the clinical relevance of pharmacogenomics within dental genomics, distinguishing clinically actionable applications from emerging or investigational findings. Materials and Methods A targeted literature review was conducted in PubMed/MEDLINE, Scopus and Embase for publications from January ...
Giorgia Pieretto   +3 more
wiley   +1 more source

CYP2C19 *2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study

open access: yesInternational Journal of General Medicine, 2023
Jieyao Xie, Tingjun Pan, Weiwen Luo, Songsheng Zhang, Yuquan Fang, Zhou Xu Intensive Care Unit, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of ChinaCorrespondence: Jieyao Xie, Intensive Care Unit, Meizhou ...
Xie J   +5 more
doaj  

Impact of Letermovir on Voriconazole Concentrations in Lung Transplant Patients

open access: yesTransplant Infectious Disease, EarlyView.
Concomitant letermovir was associated with lower voriconazole exposure and reduced attainment of commonly used efficacy thresholds in lung transplant recipients. Routine therapeutic drug monitoring after letermovir initiation is recommended, and empiric voriconazole dose escalation may be needed to avoid subtherapeutic exposure. ABSTRACT Background The
Leah Georgiades   +6 more
wiley   +1 more source

A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps

open access: yesPharmacogenomics and Personalized Medicine, 2023
Eda Eken,1,2 David S Estores,3 Emily J Cicali,1,2 Kristin K Wiisanen,1,2 Julie A Johnson1,2 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA; 2Center for Pharmacogenomics and ...
Eken E   +4 more
doaj  

Role of CYP2C19 polymorphisms in patients with endometriosis

open access: yesGynecological Endocrinology, 2009
To investigate the association of CYP2C19 genotypes with endometriosis.The study included 100 women who underwent laparotomy or laparoscopy: 50 patients with endometriosis diagnosed with surgery and histopathology, and 50 control subjects who had no evidence of endometriosis during exploratory laparotomy or laparoscopy.
Filiz, Cayan   +4 more
openaire   +2 more sources

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen

open access: yes, 2013
Montri Chamnanphon,1 Khunthong Pechatanan,2 Ekapob Sirachainan,3 Narumol Trachu,4 Wasun Chantratita,5 Ekawat Pasomsub,5 Wilai Noonpakdee,6 Insee Sensorn,1,7 Chonlaphat Sukasem11Division of Pharmacogenomics and Personalized Medicine, Department of ...
Noonpakdee W   +8 more
core  

Association between CYP2C19 polymorphism and depressive symptoms

open access: yes, 2010
Cytochrome P450 2C19 (CYP2C19) is a polymorphic enzyme active in the metabolism of for example diazepam and the antidepressants sertraline, citalopram, and escitalopram, whereby allelic variants cause increased (CYP2C19*17) or abolished (mainly CYP2C19*2)
Nordin, L   +13 more
core   +1 more source

Third Space Endoscopic Therapies for Benign Motility Disorders: A Narrative Review

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives To review the evidence base, evolution, outcomes, adverse events (AEs), and management for third‐space endoscopy (TSE) procedures for management of benign motility disorders. Methods This review examines TSE procedures for motility disorders, reviewing the current available techniques, success, outcomes, and long‐term outcomes from ...
Sanjana Bhagwat, Amol Bapaye
wiley   +1 more source

Home - About - Disclaimer - Privacy